Keyword: Samsung Biologics
Markets & Companies
11.09.2024
-
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and...
News
26.10.2023
-
Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and...
News
13.06.2023
-
South Korean CDMO Samsung Biologics has entered into a long-term manufacturing partnership with major drugmaker Pfizer.
News
08.11.2022
-
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate...
News
13.06.2022
-
In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development...
Markets & Companies
20.04.2022
-
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...
News
04.02.2022
-
Samsung Biologics has agreed to buy out partner Biogen’s share of their Samsung Bioepis joint venture for up to $2.3 billion. The South Korean group said the deal will...
News
25.05.2020
- GlaxoSmithKline has agreed an eight-year, $231 million, pact with South Korean CDMO Samsung Biologics to scale up manufacturing of biologics. The capacity Samsung provides will be...